Theravance Biopharma, Inc. Current Liabilities
Theravance Biopharma, Inc. (TBPH) had Current Liabilities of $30.77 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Liabilities, Current $30.77M.
- 2026-03-31: Liabilities, Current $31.77M.
- 2025-12-31: Liabilities, Current $38.30M.
- 2025-09-30: Liabilities, Current $37.41M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $30.77M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $31.77M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $38.30M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $37.41M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $54.63M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $31.50M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $32.09M 10-K · filed 2026-03-23 |
| 2024-09-30 | $23.43M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $22.95M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $21.66M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $24.77M 10-K · filed 2025-03-07 |
| 2023-09-30 | $25.37M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $24.55M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $26.18M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $28.71M 10-K · filed 2024-03-01 |
| 2022-09-30 | $142.13M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $32.62M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $44.20M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $58.59M 10-K · filed 2023-03-01 |
| 2021-09-30 | $66.08M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $67.13M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $86.49M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $123.57M 10-K · filed 2022-02-28 |
| 2020-09-30 | $104.27M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $106.57M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $98.04M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $111.70M 10-K · filed 2021-02-26 |
| 2019-09-30 | $108.82M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $110.14M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $113.54M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $98.55M 10-K · filed 2020-02-27 |
| 2018-09-30 | $102.03M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $93.48M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $105.18M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $62.55M 10-K · filed 2019-02-28 |
| 2017-09-30 | $48.79M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $57.10M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $48.98M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $49.27M 10-K · filed 2018-02-28 |
| 2016-09-30 | $45.41M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $44.66M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $46.40M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $49.47M 10-K · filed 2017-03-01 |
| 2015-09-30 | $27.43M 10-Q · filed 2015-11-12 |
| 2015-06-30 | $24.48M 10-Q · filed 2015-08-13 |
| 2015-03-31 | $28.85M 10-Q · filed 2015-05-13 |
| 2014-12-31 | $41.26M 10-K · filed 2016-03-11 |
| 2014-09-30 | $35.83M 10-Q · filed 2014-11-12 |
| 2014-06-30 | $40.11M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $38.54M 10-Q · filed 2014-06-24 |
| 2013-12-31 | $36.85M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |